Fred Hutchinson Cancer Center: Carcinoma trials

The registry lists 13 Carcinoma studies with Fred Hutchinson Cancer Center as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 7Phase 2 7No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Outcomes for Offering Genetic Testing in a Tiered ApproachCompletedNCT04902144Not applicableResults posted
• Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung CancerTerminatedNCT04639245Phase 1/2Results posted
• Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder CancerCompletedNCT04496219Phase 2Results posted
• Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ MalignanciesTerminatedNCT02706392Phase 1Results posted
• Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell CarcinomaTerminatedNCT02584829Phase 1/2Results posted
• CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT01881867Phase 2Results posted
• Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate CancerWithdrawnNCT06094842Phase 1
• SmartQuit Program for Smoking CessationCompletedNCT04510077Not applicable
• Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based OrganizationCompletedNCT04208724Not applicable
• Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell CarcinomaTerminatedNCT01758458Phase 1/2
• Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantCompletedNCT00078858Phase 1/2
• Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerCompletedNCT00027820Phase 1/2
• Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerCompletedNCT00005799Not applicable